Experienced in COVID-19

Michael G. Kiehl

Frankfurt (oder), BB, DE 
Experienced in COVID-19
Frankfurt (oder), BB, DE 
OverviewLocationsClinical Research

Overview

Michael Kiehl practices in Frankfurt (oder), Germany. Mr. Kiehl is rated as an Experienced expert by MediFind in the treatment of COVID-19. His top areas of expertise are Aspergillosis, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of COVID-19.

Gender
Male

Locations

Frankfurt (oder), BB, Germany
Other Locations
Frankfurt Am Main, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Enrollment Status: Unknown
Publish Date: April 27, 2023
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Bortezomib, Autologous Stem Cell Transplant, Aallogeneic Stem Cell Transplant
Study Phase: Phase 3
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Enrollment Status: Terminated
Publish Date: October 29, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

51 Total Publications

Targeted antineoplastic therapy in critically ill cancer patients: a multicenter analysis of the iCHOP registry.
Targeted antineoplastic therapy in critically ill cancer patients: a multicenter analysis of the iCHOP registry.
Journal: Annals of hematology
Published: November 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kiehl's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile